- Home
- GERN vs UTL Comparison
GERN vs UTL Comparison
Compare GERN & UTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GERN
- UTL
- Stock Information
- Founded
- GERN 1990
- UTL 1984
- Country
- GERN United States
- UTL United States
- Employees
- GERN 229
- UTL N/A
- Industry
- GERN Biotechnology: Pharmaceutical Preparations
- UTL Power Generation
- Sector
- GERN Health Care
- UTL Utilities
- Exchange
- GERN Nasdaq
- UTL Nasdaq
- Market Cap
- GERN 823.0M
- UTL 811.5M
- IPO Year
- GERN 1996
- UTL N/A
- Fundamental
- Price
- GERN $1.30
- UTL $46.27
- Analyst Decision
- GERN Buy
- UTL Hold
- Analyst Count
- GERN 8
- UTL 1
- Target Price
- GERN $3.71
- UTL $55.00
- AVG Volume (30 Days)
- GERN 6.6M
- UTL 137.6K
- Earning Date
- GERN 11-06-2025
- UTL 11-03-2025
- Dividend Yield
- GERN N/A
- UTL 3.87%
- EPS Growth
- GERN N/A
- UTL N/A
- EPS
- GERN N/A
- UTL 2.91
- Revenue
- GERN $164,447,000.00
- UTL $493,800,000.00
- Revenue This Year
- GERN $175.15
- UTL $7.06
- Revenue Next Year
- GERN $56.61
- UTL $7.63
- P/E Ratio
- GERN N/A
- UTL $15.99
- Revenue Growth
- GERN 11877.20
- UTL N/A
- 52 Week Low
- GERN $1.09
- UTL $44.61
- 52 Week High
- GERN $4.83
- UTL $63.52
- Technical
- Relative Strength Index (RSI)
- GERN 42.28
- UTL 43.66
- Support Level
- GERN $1.27
- UTL $45.11
- Resistance Level
- GERN $1.52
- UTL $46.59
- Average True Range (ATR)
- GERN 0.06
- UTL 0.91
- MACD
- GERN -0.02
- UTL 0.12
- Stochastic Oscillator
- GERN 8.00
- UTL 50.61
About GERN Geron Corporation
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.
About UTL UNITIL Corporation
Unitil Corp is a holding company, through its subsidiaries it is engaged in the local distribution of electricity and natural gas throughout its service territories in the states of New Hampshire, Massachusetts, and Maine. The Company has two operating and reportable segments: Utility Electric Operations and Utility Gas Operations. Majority of revenue is gained from Electric Segment.